CN1847261B - 作为g蛋白-偶联受体拮抗剂的环肽 - Google Patents

作为g蛋白-偶联受体拮抗剂的环肽 Download PDF

Info

Publication number
CN1847261B
CN1847261B CN2006100067952A CN200610006795A CN1847261B CN 1847261 B CN1847261 B CN 1847261B CN 2006100067952 A CN2006100067952 A CN 2006100067952A CN 200610006795 A CN200610006795 A CN 200610006795A CN 1847261 B CN1847261 B CN 1847261B
Authority
CN
China
Prior art keywords
compound
rat
antagonist
receptor
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006100067952A
Other languages
English (en)
Chinese (zh)
Other versions
CN1847261A (zh
Inventor
史蒂夫·泰勒
伊恩·A·希尔斯
戴维·费尔利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CN1847261A publication Critical patent/CN1847261A/zh
Application granted granted Critical
Publication of CN1847261B publication Critical patent/CN1847261B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
CN2006100067952A 2001-10-17 2002-10-17 作为g蛋白-偶联受体拮抗剂的环肽 Expired - Fee Related CN1847261B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8334A AUPR833401A0 (en) 2001-10-17 2001-10-17 G protein-coupled receptor antagonists
AUPR8334 2001-10-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA028252578A Division CN1604909A (zh) 2001-10-17 2002-10-17 作为g蛋白－偶联受体拮抗剂的环肽

Publications (2)

Publication Number Publication Date
CN1847261A CN1847261A (zh) 2006-10-18
CN1847261B true CN1847261B (zh) 2010-12-01

Family

ID=3832159

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028252578A Pending CN1604909A (zh) 2001-10-17 2002-10-17 作为g蛋白－偶联受体拮抗剂的环肽
CN2006100067952A Expired - Fee Related CN1847261B (zh) 2001-10-17 2002-10-17 作为g蛋白-偶联受体拮抗剂的环肽

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA028252578A Pending CN1604909A (zh) 2001-10-17 2002-10-17 作为g蛋白－偶联受体拮抗剂的环肽

Country Status (7)

Country Link
US (3) US7579432B2 (enExample)
EP (1) EP1444251A4 (enExample)
JP (1) JP2005515973A (enExample)
CN (2) CN1604909A (enExample)
AU (2) AUPR833401A0 (enExample)
CA (1) CA2463675C (enExample)
WO (1) WO2003033528A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
CA2542507C (en) * 2002-10-16 2013-04-16 The University Of Queensland Treatment of inflammatory bowel disease
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
MXPA06011051A (es) * 2004-03-26 2007-04-13 Promics Pty Ltd Tratamiento de condiciones neurologicas usando complemento de moduladores del receptor c5a.
WO2006074964A1 (en) * 2005-01-17 2006-07-20 Jerini Ag C5a receptor antagonists
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
CN101553244B (zh) * 2006-07-21 2013-01-02 普罗米克斯有限公司 内膜增生和相关病状的治疗
WO2008153962A2 (en) * 2007-06-08 2008-12-18 The Trustees Of The University Of Pennylvania Method of reducing tissue loss in pancreatic islet cell transplantation
US8563259B2 (en) * 2007-06-29 2013-10-22 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US10632170B2 (en) * 2008-02-19 2020-04-28 The Trustees Of The University Of Pennsylvania Administration of compstatin to an individual for the treatment of a tumor
EP2331113A4 (en) * 2008-08-20 2012-03-14 Univ Pennsylvania COMPLEMENTARY TREATMENT FOR THE TREATMENT OF LESIONS DUE TO BRAIN BLEEDING
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US20140219999A1 (en) 2011-04-01 2014-08-07 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US20200325449A1 (en) 2016-06-02 2020-10-15 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
JP2019532021A (ja) * 2016-07-29 2019-11-07 ファイザー・インク Ｃ５ａ受容体アンタゴニストとしての環状ペプチド
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
ES2893769T3 (es) 2017-04-03 2022-02-10 Inflarx Gmbh Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a
CN111201241A (zh) * 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
SG10201902000YA (en) * 2019-03-06 2020-10-29 Nat Univ Singapore Isthmin 1 for treatment of lung inflammation
IL296036A (en) 2020-03-27 2022-10-01 Inflarx Gmbh Inhibitors of c5a for the treatment of corona virus infection
FR3112941B1 (fr) * 2020-07-30 2023-03-03 Sederma Sa Traitement cosmétique ou dermatologique à base de peptide(s) de la peau et de ses phanères
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド
CN116311497A (zh) * 2023-02-02 2023-06-23 山东大学 一种基于机器视觉的隧道工人异常行为检测方法及系统
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists

Also Published As

Publication number Publication date
AUPR833401A0 (en) 2001-11-08
US20100331236A1 (en) 2010-12-30
AU2002336783B2 (en) 2008-11-06
CN1604909A (zh) 2005-04-06
EP1444251A1 (en) 2004-08-11
CA2463675A1 (en) 2003-04-24
EP1444251A4 (en) 2005-12-21
JP2005515973A (ja) 2005-06-02
US20120302493A1 (en) 2012-11-29
CN1847261A (zh) 2006-10-18
US20060217530A1 (en) 2006-09-28
US7579432B2 (en) 2009-08-25
WO2003033528A1 (en) 2003-04-24
CA2463675C (en) 2012-08-07

Similar Documents

Publication Publication Date Title
CN1847261B (zh) 作为g蛋白-偶联受体拮抗剂的环肽
US20230106577A1 (en) Peptidomimetic macrocycles and uses thereof
JP5140686B2 (ja) テンプレート固定ペプチド模倣薬
JP4686696B2 (ja) Ｃ５ａ受容体およびＧタンパク質結合受容体の環状アゴニストおよびアンタゴニスト
EP2246064A1 (en) Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof
AU2002336783A1 (en) Cyclic peptides as G-protein-coupled receptor antagonists
Di Maro et al. Exploring the N-terminal region of CXC motif chemokine 12 (CXCL12): identification of plasma-stable cyclic peptides as novel, potent CXC chemokine receptor type 4 (CXCR4) antagonists
CN114478707B (zh) 一种构象锁定蜂毒肽衍生物、偶联物及其制备和用途
Wong et al. The therapeutic anticancer potential of marine-derived bioactive peptides: a highlight on pardaxin
Martin-Malpartida et al. Conformational ensemble of the TNF-derived peptide solnatide in solution
CN119661641B (zh) 一种dr8环肽类似物及其应用
Chen et al. Unleashing the potential of natural biological peptide Macropin: Hydrocarbon stapling for effective breast cancer treatment
WO2004099238A1 (en) NOVEL mu-CONOTOXIN PEPTIDES
CN113861269B (zh) Dr8多肽类似物及其制备方法和应用
EP3269727B1 (en) Anti-hepatitis b virus x protein polypeptide pharmaceutical
Bayó‐Puxan et al. Combined use of oligopeptides, fragment libraries, and natural compounds: a comprehensive approach to sample the druggability of vascular endothelial growth factor
CN113024635A (zh) 一类订书肽化合物及其药物组合物的用途
Palladino et al. A simplified model of the binding interaction between stromal cell-derived factor-1 chemokine and CXC chemokine receptor 4
Staśkiewicz et al. Constrained secondary structures to develop bioactive peptides and peptidomimetics
Zhang et al. Preparation and characterization of fetal rat renal cell peptides for their antitumor activity
CN116199737A (zh) 一种低分子人表皮细胞自噬调控肽dkx-9及其应用
CN118255843A (zh) 一种靶向tead-vgl4相互作用的订书肽及其在皮肤修复中的应用
CN117442745A (zh) 一种靶向治疗胶质母细胞瘤的脂质体给药体系及其制备方法与应用
CN116102618A (zh) 多肽PYRAE、其制备方法及作为BiP抑制剂在制备抗癌药物中的应用
HK40043424A (en) Peptidomimetic macrocycles and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101201

Termination date: 20131017